TY - JOUR T1 - A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 1426 LP - 1431 DO - 10.1136/annrheumdis-2016-210742 VL - 76 IS - 8 AU - Bente Glintborg AU - Inge Juul Sørensen AU - Anne Gitte Loft AU - Hanne Lindegaard AU - Asta Linauskas AU - Oliver Hendricks AU - Inger Marie Jensen Hansen AU - Dorte Vendelbo Jensen AU - Natalia Manilo AU - Jakob Espesen AU - Mette Klarlund AU - Jolanta Grydehøj AU - Sabine Sparre Dieperink AU - Salome Kristensen AU - Jimmi Sloth Olsen AU - Henrik Nordin AU - Stavros Chrysidis AU - Dorte Dalsgaard Pedersen AU - Michael Veedfald Sørensen AU - Lis Smedegaard Andersen AU - Kathrine Lederballe Grøn AU - Niels Steen Krogh AU - Lars Pedersen AU - Merete Lund Hetland A2 - , Y1 - 2017/08/01 UR - http://ard.bmj.com/content/76/8/1426.abstract N2 - Objectives According to guidelines, a nationwide non-medical switch from originator (INX, Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). We investigated disease activity before/after switching and retention rates in the DANBIO registry.Methods Disease activities 3 months before and after switch and changes over time were calculated. Flare was defined as change in 28 Joint Disease Activity Score (∆DAS28) ≥1.2 (RA/PsA) or Ankylosing Spondylitis Disease Activity Score (∆ASDAS) ≥1.3 (AxSpA). Crude and adjusted retention rates were compared with a historic cohort of INX-treated patients.Results Eight hundred and two patients switched (403 RA/120 PsA/279 AxSpA; 51% women, age (median (IQR): 55 (44-66)) years). Follow-up was 413 (339–442) days. Prior INX treatment duration was 6.8 (4.3–9.5) years. Disease activities were similar 3 months before/after switch. Crude 1-year CT-P13 retention rate (84.1 (95% CI 81.3 to 86.5)) was similar to the historic IFX cohort (86.2 (95% CI 84.0 to 88.0), p=0.22). The adjusted absolute retention rates were 83.4 (95% CI 80.8 to 86.2) and 86.8% (95% CI 84.8 to 88.8), respectively (p=0.03). In total 132 patients withdrew (lack of effect: 71/132=54%, adverse events: 37/132=28%). Patients with previous INX treatment duration >5 years had longer CT-P13 retention.Conclusion In 802 arthritis patients treated with INX for median >6 years, a nationwide non-medical switch to CT-P13 had no negative impact on disease activity. Adjusted 1-year CT-P13 retention rate was slightly lower than for INX in a historic cohort. ER -